Companies House 2023-10-05 2025-10-31 2025-10-31 false true iso4217:GBP xbrli:pure 15191029 2025-10-31 15191029 2023-10-05 2025-10-31 15191029 curr:PoundSterling 2023-10-05 2025-10-31 15191029 uk-bus:PrivateLimitedCompanyLtd 2023-10-05 2025-10-31 15191029 uk-bus:FRS102 2023-10-05 2025-10-31 15191029 uk-bus:AuditExempt-NoAccountantsReport 2023-10-05 2025-10-31 15191029 uk-bus:AbridgedAccounts 2023-10-05 2025-10-31 15191029 uk-bus:RegisteredOffice 2023-10-05 2025-10-31 15191029 uk-bus:Director40 2023-10-05 2025-10-31 15191029 uk-bus:Director1 2023-10-05 2025-10-31 15191029 uk-bus:Director2 2023-10-05 2025-10-31 15191029 uk-bus:Director3 2023-10-05 2025-10-31 15191029 uk-bus:Director4 2023-10-05 2025-10-31 15191029 uk-bus:Director5 2023-10-05 2025-10-31 15191029 uk-bus:Director6 2023-10-05 2025-10-31 15191029 uk-bus:Director7 2023-10-05 2025-10-31 15191029 uk-bus:Director8 2023-10-05 2025-10-31 15191029 uk-bus:Director9 2023-10-05 2025-10-31 15191029 uk-bus:Director10 2023-10-05 2025-10-31 15191029 uk-bus:Director11 2023-10-05 2025-10-31 15191029 uk-bus:Director12 2023-10-05 2025-10-31 15191029 uk-bus:Director13 2023-10-05 2025-10-31 15191029 uk-bus:Director14 2023-10-05 2025-10-31 15191029 uk-bus:Director15 2023-10-05 2025-10-31 15191029 uk-bus:Director16 2023-10-05 2025-10-31 15191029 uk-bus:Director17 2023-10-05 2025-10-31 15191029 uk-bus:Director18 2023-10-05 2025-10-31 15191029 uk-bus:Director19 2023-10-05 2025-10-31 15191029 uk-bus:Director20 2023-10-05 2025-10-31 15191029 uk-bus:CompanySecretary1 2023-10-05 2025-10-31 15191029 core:AfterOneYear 2025-10-31 15191029 core:WithinOneYear 2025-10-31 15191029 core:WithinOneYear 2023-10-05 2025-10-31 15191029 core:AfterOneYear 2025-10-31 15191029 core:AfterOneYear 2023-10-05 2025-10-31 15191029 core:ShareCapital 2025-10-31 15191029 core:SharePremium 2025-10-31 15191029 core:OtherReservesSubtotal 2025-10-31 15191029 core:RevaluationReserve 2025-10-31 15191029 core:RetainedEarningsAccumulatedLosses 2025-10-31 15191029 core:Associate1 2023-10-05 2025-10-31 15191029 core:Associate1 2025-10-31 15191029 core:Associate2 2023-10-05 2025-10-31 15191029 core:Associate2 2025-10-31 15191029 core:Associate3 2023-10-05 2025-10-31 15191029 core:Associate3 2025-10-31 15191029 core:Associate4 2023-10-05 2025-10-31 15191029 core:Associate4 2025-10-31 15191029 core:Associate5 2023-10-05 2025-10-31 15191029 core:Associate5 2025-10-31 15191029 core:Associate6 2023-10-05 2025-10-31 15191029 core:Associate6 2025-10-31 15191029 core:Associate7 2023-10-05 2025-10-31 15191029 core:Associate7 2025-10-31 15191029 core:Associate8 2023-10-05 2025-10-31 15191029 core:Associate8 2025-10-31 15191029 core:Associate9 2023-10-05 2025-10-31 15191029 core:Associate9 2025-10-31 15191029 core:Associate10 2023-10-05 2025-10-31 15191029 core:Associate10 2025-10-31 15191029 core:Associate11 2023-10-05 2025-10-31 15191029 core:Associate11 2025-10-31 15191029 core:Associate12 2023-10-05 2025-10-31 15191029 core:Associate12 2025-10-31 15191029 core:Associate13 2023-10-05 2025-10-31 15191029 core:Associate13 2025-10-31 15191029 core:Associate14 2023-10-05 2025-10-31 15191029 core:Associate14 2025-10-31 15191029 core:Associate15 2023-10-05 2025-10-31 15191029 core:Associate15 2025-10-31 15191029 core:Associate16 2023-10-05 2025-10-31 15191029 core:Associate16 2025-10-31 15191029 core:Associate17 2023-10-05 2025-10-31 15191029 core:Associate17 2025-10-31 15191029 core:Associate18 2023-10-05 2025-10-31 15191029 core:Associate18 2025-10-31 15191029 core:Associate19 2023-10-05 2025-10-31 15191029 core:Associate19 2025-10-31 15191029 core:Associate20 2023-10-05 2025-10-31 15191029 core:Associate20 2025-10-31 15191029 core:Associate1 2023-10-05 2025-10-31 15191029 core:Associate2 2023-10-05 2025-10-31 15191029 core:Associate3 2023-10-05 2025-10-31 15191029 core:Associate4 2023-10-05 2025-10-31 15191029 core:Associate5 2023-10-05 2025-10-31 15191029 core:Associate6 2023-10-05 2025-10-31 15191029 core:Associate7 2023-10-05 2025-10-31 15191029 core:Associate8 2023-10-05 2025-10-31 15191029 core:Associate9 2023-10-05 2025-10-31 15191029 core:Associate10 2023-10-05 2025-10-31 15191029 core:Associate11 2023-10-05 2025-10-31 15191029 core:Associate12 2023-10-05 2025-10-31 15191029 core:Associate13 2023-10-05 2025-10-31 15191029 core:Associate14 2023-10-05 2025-10-31 15191029 core:Associate15 2023-10-05 2025-10-31 15191029 core:Associate16 2023-10-05 2025-10-31 15191029 core:Associate17 2023-10-05 2025-10-31 15191029 core:Associate18 2023-10-05 2025-10-31 15191029 core:Associate19 2023-10-05 2025-10-31 15191029 core:Associate20 2023-10-05 2025-10-31 15191029 uk-bus:Director1 1 2023-10-05 2025-10-31 15191029 uk-bus:Director1 1 2025-10-31 15191029 uk-bus:Director2 2 2023-10-05 2025-10-31 15191029 uk-bus:Director2 2 2025-10-31 15191029 uk-bus:Director1 3 2023-10-05 2025-10-31 15191029 uk-bus:Director1 3 2025-10-31 15191029 uk-bus:Director4 4 2023-10-05 2025-10-31 15191029 uk-bus:Director4 4 2025-10-31 15191029 uk-bus:Director5 5 2023-10-05 2025-10-31 15191029 uk-bus:Director5 5 2025-10-31 15191029 uk-bus:Director6 6 2023-10-05 2025-10-31 15191029 uk-bus:Director6 6 2025-10-31 15191029 uk-bus:Director7 7 2023-10-05 2025-10-31 15191029 uk-bus:Director7 7 2025-10-31 15191029 uk-bus:Director8 8 2023-10-05 2025-10-31 15191029 uk-bus:Director8 8 2025-10-31 15191029 uk-bus:Director9 9 2023-10-05 2025-10-31 15191029 uk-bus:Director9 9 2025-10-31 15191029 uk-bus:Director10 10 2023-10-05 2025-10-31 15191029 uk-bus:Director10 10 2025-10-31 15191029 uk-bus:Director11 11 2023-10-05 2025-10-31 15191029 uk-bus:Director11 11 2025-10-31 15191029 uk-bus:Director12 12 2023-10-05 2025-10-31 15191029 uk-bus:Director12 12 2025-10-31 15191029 uk-bus:Director13 13 2023-10-05 2025-10-31 15191029 uk-bus:Director13 13 2025-10-31 15191029 uk-bus:Director14 14 2023-10-05 2025-10-31 15191029 uk-bus:Director14 14 2025-10-31 15191029 uk-bus:Director15 15 2023-10-05 2025-10-31 15191029 uk-bus:Director15 15 2025-10-31 15191029 uk-bus:Director16 16 2023-10-05 2025-10-31 15191029 uk-bus:Director16 16 2025-10-31 15191029 uk-bus:Director17 17 2023-10-05 2025-10-31 15191029 uk-bus:Director17 17 2025-10-31 15191029 uk-bus:Director18 18 2023-10-05 2025-10-31 15191029 uk-bus:Director18 18 2025-10-31 15191029 uk-bus:Director19 19 2023-10-05 2025-10-31 15191029 uk-bus:Director19 19 2025-10-31 15191029 uk-bus:Director20 20 2023-10-05 2025-10-31 15191029 uk-bus:Director20 20 2025-10-31 15191029 1 2023-10-05 2025-10-31 15191029 2 2023-10-05 2025-10-31 15191029 3 2023-10-05 2025-10-31

# VESPULA THERAPEUTICS LTD

## Company Registration Number:
15191029 (England and Wales)

## Unaudited abridged accounts for the year ended 31 October 2025

## Period of accounts

## Start date: 05 October 2023

## End date: 31 October 2025

# VESPULA THERAPEUTICS LTD

## Contents of the Financial Statements

for the Period Ended 31 October 2025

Balance sheet |
Notes |

# VESPULA THERAPEUTICS LTD

## Balance sheet

As at 31 October 2025

| Notes | 25 months to 31 October 2025
--- | --- | ---
|  | £
Called up share capital not paid: |  | 0
Fixed assets
Intangible assets: | 3 | 416,300
Tangible assets: |  | 0
Investments: |  | 0
Total fixed assets: |  | 416,300
Current assets
Stocks: |  | 0
Debtors: |  | 0
Cash at bank and in hand: |  | 138,167
Investments: |  | 0
Total current assets: |  | 138,167
Creditors: amounts falling due within one year: | 4 | (33,587)
Net current assets (liabilities): |  | 104,580
Total assets less current liabilities: |  | 520,880
Creditors: amounts falling due after more than one year: | 5 | (1,134,388)
Provision for liabilities: |  | 0
Total net assets (liabilities): |  | (613,508)
Capital and reserves
Called up share capital: |  | 3
Share premium account: |  | 0
Revaluation reserve: | 6 | (59,651)
Other reserves: |  | 0
Profit and loss account: |  | (553,860)
Shareholders funds: |  | (613,508)

The notes form part of these financial statements

# VESPULA THERAPEUTICS LTD

## Balance sheet statements

For the year ending 31 October 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 22 July 2026
and signed on behalf of the board by:

Name: Vasily Fedorin
Status: Director

The notes form part of these financial statements

# VESPULA THERAPEUTICS LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

## 1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

# VESPULA THERAPEUTICS LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

## 2. Employees

| 25 months to 31 October 2025
--- | ---
Average number of employees during the period | 0

# VESPULA THERAPEUTICS LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

## 3. Intangible Assets

| Total
--- | ---
Cost | £
Additions | 416,300
Disposals | 0
Revaluations | 0
Transfers | 0
At 31 October 2025 | 416,300
Amortisation |
Charge for year | 0
On disposals | 0
Other adjustments | 0
At 31 October 2025 | 0
Net book value |
At 31 October 2025 | 416,300

# VESPULA THERAPEUTICS LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

## 4. Creditors: amounts falling due within one year note

Suspense account

# VESPULA THERAPEUTICS LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

## 5. Creditors: amounts falling due after more than one year note

Loan from 4BIO Ventures II

# VESPULA THERAPEUTICS LTD

## Notes to the Financial Statements

for the Period Ended 31 October 2025

## 6. Revaluation reserve

| 25 months to 31 October 2025
--- | ---
| £
Surplus or deficit after revaluation | (59,651)
Balance at 31 October 2025 | (59,651)